Patricia Shuhaiber
Patricia Shuhaiber has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Carole Dib
Pharmacy Department, Lebanese Hospital Geitaoui University Medical Center, Beirut, Lebanon
2 shared publications- Rania Itani
Affiliation Pharmacy Practice Department, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon
2 shared publications Abdalla El-Lakany
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon
1 shared publication- Aline Hajj
INSPECT-LB (Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie-Liban), Beirut, Lebanon
1 shared publication Aya Ali Ahmad
Pharmacy Practice Department, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon
1 shared publication- Elie Salem Sokhn
Beirut Arab University
1 shared publication
Latest Publications
- Open Access
- 5 June 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (8) , 103282
Epidemiology, antimicrobial resistance patterns, management, and predictors of mortality in diabetic foot infections in a Lebanese hospital: A retrospective observational study
- 5 June 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (8) , 103282
Open AccessEpidemiology, antimicrobial resistance patterns, management, and predictors of mortality in diabetic foot infections in a Lebanese hospital: A retrospective observational study
- Open Access
- 20 August 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Incidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals
The emergence of difficult-to-treat resistant (DTR) Pseudomonas aeruginosa infections poses a significant clinical challenge, characterized by limited treatment options, poor outcomes, and increased morbidity and mortality. DTR P. aeruginosa isolates exhibit resistance to all first-line antibiotics, necessitating the use of less effective or more toxic alternatives. This study estimated the incidence of DTR P. aeruginosa infections in Lebanon and identified the associated risk factors. This retrospective observational study was conducted across four tertiary care centers in Beirut, Lebanon, over a three-year period from 2021 to 2023. Univariate and multivariate logistic regression analyses were performed to identify significant predictors associated with DTR P. aeruginosa infections. A total of 2,639 cases with positive P. aeruginosa isolates were initially screened, with 477 cases meeting the inclusion criteria for analysis. The mean age of the patients was 66.3 ± 17.8 years, and the mean Charlson Comorbidity Index was 4.46 ± 2.43. Nearly half of the infections were nosocomial (47.6%). The most common primary site of infection was the respiratory tract (38.8%), followed by skin and soft tissue (32.7%). The incidence of DTR P. aeruginosa was 15.3%, and the incidence of carbapenem-resistant P. aeruginosa (CRPA) was 29.9%. Binary logistic regression identified three main risk factors for DTR P. aeruginosa infection acquisition: infections occurring during the winter season (adjusted odds ratio [AOR] = 6.08, 95% CI = 2.75–16.13, P < 0.01), intensive care unit stay (AOR = 2.52, 95% CI = 1.28–4.98, P < 0.01), and infections originating from the respiratory tract (AOR = 2.49, 95% CI = 1.04–5.97, P = 0.04). The incidence of DTR P. aeruginosa in Lebanese hospitals is substantial compared to global rates and poses a significant challenge to effective treatment. Urgent measures are required to prevent and mitigate the spread of DTR P. aeruginosa infections. Hospital-based antimicrobial stewardship and infection control programs need to be reinforced, and community-based initiatives should be implemented at the national level. Efforts to combat antimicrobial resistance must be supported by ongoing nationwide annual surveillance.
- 20 August 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Open AccessIncidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals
The emergence of difficult-to-treat resistant (DTR) Pseudomonas aeruginosa infections poses a significant clinical challenge, characterized by limited treatment options, poor outcomes, and increased morbidity and mortality. DTR P. aeruginosa isolates exhibit resistance to all first-line antibiotics, necessitating the use of less effective or more toxic alternatives. This study estimated the incidence of DTR P. aeruginosa infections in Lebanon and identified the associated risk factors. This retrospective observational study was conducted across four tertiary care centers in Beirut, Lebanon, over a three-year period from 2021 to 2023. Univariate and multivariate logistic regression analyses were performed to identify significant predictors associated with DTR P. aeruginosa infections. A total of 2,639 cases with positive P. aeruginosa isolates were initially screened, with 477 cases meeting the inclusion criteria for analysis. The mean age of the patients was 66.3 ± 17.8 years, and the mean Charlson Comorbidity Index was 4.46 ± 2.43. Nearly half of the infections were nosocomial (47.6%). The most common primary site of infection was the respiratory tract (38.8%), followed by skin and soft tissue (32.7%). The incidence of DTR P. aeruginosa was 15.3%, and the incidence of carbapenem-resistant P. aeruginosa (CRPA) was 29.9%. Binary logistic regression identified three main risk factors for DTR P. aeruginosa infection acquisition: infections occurring during the winter season (adjusted odds ratio [AOR] = 6.08, 95% CI = 2.75–16.13, P < 0.01), intensive care unit stay (AOR = 2.52, 95% CI = 1.28–4.98, P < 0.01), and infections originating from the respiratory tract (AOR = 2.49, 95% CI = 1.04–5.97, P = 0.04). The incidence of DTR P. aeruginosa in Lebanese hospitals is substantial compared to global rates and poses a significant challenge to effective treatment. Urgent measures are required to prevent and mitigate the spread of DTR P. aeruginosa infections. Hospital-based antimicrobial stewardship and infection control programs need to be reinforced, and community-based initiatives should be implemented at the national level. Efforts to combat antimicrobial resistance must be supported by ongoing nationwide annual surveillance.
- 27 December 2018
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 25 (2) , 323-339
Medication safety knowledge, attitude, and practice among hospital pharmacists in Lebanon
Background: Studies showed that pharmacists have little experience with adverse drug reactions (ADRs) reporting due to insufficient knowledge of the concept of ADR and pharmacovigilance (PV). There is an urge to assess hospital pharmacists' knowledge in medication safety practices.Objective: To evaluate the knowledge, attitude, and practice, among hospital pharmacists in Lebanon concerning ADRs and PV concepts.Methods: A cross‐sectional study, conducted between March and July 2016, enrolled 187 hospital pharmacists in all Lebanese districts.Results: Concerning knowledge, 60.8% of the pharmacists said that ADR is an injury caused by appropriate and suboptimal care, while 74.6% of them said it can be preventable and nonpreventable. Moreover, 47.5% of them defined PV as being the study that detects, assesses, understands, and prevents adverse effects. Furthermore, 55.1% believed that PV concerns drug, herbal, medical devices, and vaccine problems. Concerning attitude, 61% of the pharmacists said they do not support direct ADR reporting by the patient. Of them, 78.6% confessed that ADR reporting is a professional obligation to them while 88.2% admitted that it is time‐consuming with no outcome. When it comes to practice, 64.2% had been trained to report ADRs. Only 20.8% and 24.2% confessed reporting ADRs more than once a week, respectively. More than half (54.5%) said that they report the ADR to the patient's prescriber.Conclusion: Lebanese hospital pharmacists have little knowledge about the concept and process of PV and spontaneous ADRs reporting system. However, these pharmacists have positive attitudes, but very little practice with reporting systems. Educational programs are urgently needed to emphasize the role and responsibility of pharmacists in PV practices and to raise awareness towards ADR reporting process.
- 27 December 2018
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 25 (2) , 323-339
Medication safety knowledge, attitude, and practice among hospital pharmacists in Lebanon
Background: Studies showed that pharmacists have little experience with adverse drug reactions (ADRs) reporting due to insufficient knowledge of the concept of ADR and pharmacovigilance (PV). There is an urge to assess hospital pharmacists' knowledge in medication safety practices.Objective: To evaluate the knowledge, attitude, and practice, among hospital pharmacists in Lebanon concerning ADRs and PV concepts.Methods: A cross‐sectional study, conducted between March and July 2016, enrolled 187 hospital pharmacists in all Lebanese districts.Results: Concerning knowledge, 60.8% of the pharmacists said that ADR is an injury caused by appropriate and suboptimal care, while 74.6% of them said it can be preventable and nonpreventable. Moreover, 47.5% of them defined PV as being the study that detects, assesses, understands, and prevents adverse effects. Furthermore, 55.1% believed that PV concerns drug, herbal, medical devices, and vaccine problems. Concerning attitude, 61% of the pharmacists said they do not support direct ADR reporting by the patient. Of them, 78.6% confessed that ADR reporting is a professional obligation to them while 88.2% admitted that it is time‐consuming with no outcome. When it comes to practice, 64.2% had been trained to report ADRs. Only 20.8% and 24.2% confessed reporting ADRs more than once a week, respectively. More than half (54.5%) said that they report the ADR to the patient's prescriber.Conclusion: Lebanese hospital pharmacists have little knowledge about the concept and process of PV and spontaneous ADRs reporting system. However, these pharmacists have positive attitudes, but very little practice with reporting systems. Educational programs are urgently needed to emphasize the role and responsibility of pharmacists in PV practices and to raise awareness towards ADR reporting process.